BioSpace News Archive

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the the voting results from its Annual General Meeting of Shareholders held on Thursday May 7, 2020.

Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a global commercial manufacturer of high quality cannabinoid-based ingredients, formulations and products, announces that it has entered into a series of shares for debt agreements with various of its creditors under the terms and conditions noted below.

Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2020. Second Quarter Fiscal 2020 Highlights: Consolidated Net Revenue of $57.3 million, up 14% year-over-year Life Science segment responded early and swiftly to the COVID-19 pandemic contributing to a record $22.4 million in revenues, up 33% year-over-year Diagnostics segment delivered over $34.9 million in revenue, the fifth con

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), will report financial results for the third quarter of fiscal year

Obalon Therapeutics, Inc., a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that William Plovanic, the Company’s President and CEO has announced his resignation in order to accept another position.

Insala, provider of the most comprehensive suite of cloud-based solutions supporting the employee career lifecycle, is proud to announce that it is launching a new ground-breaking platform to facilitate interaction and learning on the COVID-19 global pandemic, its short-term and long-term implications

Results Suggest Highly Effective Method to Treat Ventricular Tachycardia, a Leading Cause of Sudden Cardiac Death

Myosrens to host conference call today

Meeting to Be Held on Friday, May 29, 2020 in Virtual-Only Format

jCyte Inc., a biotech company dedicated to improving the lives of patients with rare degenerative retinal diseases, today announced it has entered into a licensing agreement with Santen Pharmaceutical to develop and commercialize its first-in-class, investigational therapy, jCell, outside the U.S., in regions including Europe, Asia and Japan.